U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Implanted Blood Access Devices for Hemodialysis
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Implanted Blood Access Devices for Hemodialysis Guidance for Industry and Food and Drug Administration Staff January 2016

Download the Final Guidance Document
Final
Docket Number:
FDA-2013-D-0749
Issued by:
Guidance Issuing Office
Center for Devices and Radiological Health

This guidance document provides recommendations for complying with special controls issued as part of the reclassification of Implanted Blood Access Devices for Hemodialysis into class II (special controls). The devices are intended to provide access to a patient’s blood for hemodialysis.

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2013-D-0749.

Back to Top